

**Microbiome, Metabolism, and Immunoregulation of Asthma:
An American Thoracic Society and National Institute of Allergy and Infectious Diseases
Joint Workshop report**

Ariangela J. Kozik PhD¹, Fernando Holguin MD², Leopoldo N. Segal MD (ORCID 0000-0003-3559-9431)³, Talal A. Chatila MD⁴, Anne E. Dixon BM BCh⁵, James E. Gern MD (ORCID 0000-0002-6667-4708)⁶, Catherine Lozupone PhD⁷, Nicholas Lukacs PhD⁸, Carey Lumeng MD PhD^{9,10}, Philip L Molyneaux MD PhD (ORCID 0000-0003-1301-8800)¹¹, Nichole Reisdorph PhD¹², Ivan Vujkovic-Cvijin PhD¹³, Alkis Togias MD (ORCID 0000-0001-9009-5717)¹⁴, and Yvonne J. Huang MD^{1,15} (ORCID 0000-0002-7497-6597)* on behalf of the American Thoracic Society and the National Institute of Allergy and Infectious Diseases

¹ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor

² Division of Pulmonary and Critical Care Medicine, University of Colorado

³ Division of Pulmonary, Critical Care Medicine, and Sleep Medicine, New York University School of Medicine

⁴ Division of Immunology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA

⁵ Division of Pulmonary and Critical Care Medicine, University of Vermont, Burlington

⁶ Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of Wisconsin, Madison, WI

⁷ Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Campus

⁸ Department of Pathology, University of Michigan, Ann Arbor

⁹ Division of Pediatric Pulmonology, Department of Pediatrics

¹⁰ Department of Molecular and Integrative Physiology; University of Michigan, Ann Arbor

¹¹ National Heart and Lung Institute, Imperial College London, London, United Kingdom

¹² Department of Pharmaceutical Sciences, University of Colorado Anschutz Campus

¹³ Metaorganism Immunity Section, Laboratory of Immune Systems Biology, NIAID/NIH, Bethesda, MD

¹⁴ Allergy, Asthma and Airway Biology Branch; NIAID/NIH, Bethesda, MD

¹⁵ Department of Microbiology and Immunology, University of Michigan, Ann Arbor

***Corresponding Author:**

Yvonne J. Huang MD

6301 Medical Science Research Building-3,

1150 W. Medical Center Drive

Ann Arbor, MI 48109.

Email: yvjhuang@umich.edu

Phone: (734) 936-5201

Fax: (734) 764-4556

Word count: 3,756

Key Words: microbiota, metabolites, phenotype, obesity, translational studies

Disclaimer: Dr. Togias' co-authorship and the NIAID name in the title of this publication do not constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, or any agency of the US government.

For Review Only

ABSTRACT

This report presents the proceedings from a workshop entitled “Microbiome, Metabolism and Immunoregulation of Asthma” that was held **virtually** May 13th-14th, 2021. The workshop was jointly sponsored by the American Thoracic Society (Assembly on Allergy, Immunology, and Inflammation) and the National Institute of Allergy and Infectious Diseases. It convened an inter-disciplinary group of experts with backgrounds in asthma immunology, microbiome science, metabolomics, computational biology, and translational pulmonary research. The main purpose was to identify key scientific gaps and needs to further advance research on microbial and metabolic mechanisms that may contribute to variable immune responses and disease heterogeneity in asthma. Discussions were structured around several topics that included: (1) immune and microbial mechanisms of asthma pathogenesis in murine models; (2) the role of microbes in pediatric asthma exacerbations; (3) dysregulated metabolic pathways in asthma associated with obesity; (4) metabolism effects on macrophage function in adipose tissue and the lungs; (5) computational approaches to dissect microbiome-metabolite links, and (6) potential confounders of microbiome-disease associations in human studies. This report summarizes the major points of discussion which included identification of specific knowledge gaps, challenges, and suggested directions for future research. These include questions surrounding mechanisms by which microbiota and metabolites shape host health versus allergic or asthmatic state, direct and indirect influences of other biological factors, exposures and comorbidities on these interactions, and ongoing technical and analytical gaps for clinical translation.

TABLE OF CONTENTS

Introduction

Methods

Presentations and Discussions

Immune and microbial mechanisms of asthma pathogenesis in murine models

The role of microbes in pediatric asthma exacerbations

Dysregulated metabolic pathways in asthma associated with obesity

Metabolism effects on macrophage function in adipose tissue and the lungs

Computational approaches to dissect microbiome-metabolite links

Potential confounders of microbiome-disease associations in human studies.

Conclusions

OVERVIEW

Multiple scientific directions must be bridged to better understand links between perturbed microbiome and metabolic states, airway immune activity, and asthma pathophysiology. Further knowledge of functional mechanisms through which microbiota and metabolites regulate host health or shape the development and persistence of asthma is still needed. This interdisciplinary workshop was formed to identify the challenges and needs that currently hamper progress in these areas. Key points include:

- Microbiome functions and metabolic states can shape immune responses and asthma outcomes across the lifespan.
- Better understanding of how microbiota and metabolites together regulate or alter immune functions is needed, including their effects on asthma pathophysiology. Key conceptual questions are described in **Box 1**.
- Improved clinical study designs, technical platforms/resources and integrated data analysis methods will help drive further advancement in this field. Specific recommendations for future research are described in **Box 2**.

INTRODUCTION

Asthma is a complex chronic airway disease that affects patients across the lifespan. Its manifestations in early life, adolescence, and adulthood share common threads, but are otherwise heterogenous, suggesting multiple underlying etiologies. Likewise, divergent clinical outcomes highlight the needs for a more precise understanding of asthma pathophysiology. The foundations for allergy-related asthma and its manifestations are often set in early life and childhood. However, sex-related trends in asthma prevalence shift after puberty [1]. Many phenotypes of adult asthma have been described, but the mechanisms for most remain incompletely understood [2]. Asthma characterized by predominant type 2 (T2) inflammation is the best understood endophenotype with targeted therapies available. Yet, sub-optimal treatment responses are not uncommon. Additionally, a large proportion of patients have asthma without significant T2 inflammation [3] or display a mix of T2 and non-T2 inflammation, for which no precise therapies or biomarkers currently exist. These include later-onset asthma phenotypes such as obesity-associated disease.

Differences in airway immune responses contribute to variation between asthma patients in disease phenotypes and treatment response [4], but the pathobiological drivers are not fully understood. Incomplete or lack of expected treatment responses, even in those receiving biologics that target specific immune components, implicate additional factors and adjunct pathways of disease activation. Recent research has yielded cumulative evidence highlighting important links between asthma, altered microbiome characteristics (gut and airways), and perturbed metabolic states including microbial-derived mediators [5-10]. Systemic markers of inflammation, inflammasome activation, and metabolic dysregulation also are prominent in some

asthma patients and associate with more severe disease [11-15]. In parallel, advances in the immunometabolism field have highlighted that effector properties of innate and adaptive immune cells are modulated by their environment [16]. Cellular metabolism could be influenced by the presence of an altered microbiome and extracellular metabolic milieu. The impact of such on the activation and regulation of innate and adaptive immune functions implicated in asthma could be significant based on recent growing evidence [17,18], but human translation of current knowledge remains nascent.

To address this topic, a workshop jointly sponsored by the American Thoracic Society (ATS) and the National Institute of Allergy and Infectious Diseases (NIAID) was held virtually May 13-14, 2021. The overall purpose was to identify challenges and needs that currently hamper progress in understanding how altered microbiome and metabolic states intersect to shape immune responses and disease phenotype in asthma. The participants represented an interdisciplinary group of scientists with expertise across these topics, including from outside the asthma field. This report summarizes these discussions. Key gaps and challenges identified by the panel, along with suggested future research directions, are summarized in Boxes 1 and 2.

METHODS

The topic of this workshop was conceived during informal discussions among members of the ATS Assembly on Allergy, Immunology, and Inflammation and further discussed with the NIAID Allergy, Asthma, and Airway Biology Branch (Alkis Togias MD) to determine interest in convening a jointly sponsored workshop. A proposal was then submitted by Yvonne Huang MD (workshop chair) to the ATS for formal approval of the project. The workshop originally was to be held in-person at the time of the ATS International Conference in 2020 but delayed due to the

interceding SARS-CoV-2 pandemic. It was subsequently re-organized for 2021 and conducted virtually over two consecutive days, following the same originally approved meeting structure and participant roster.

Selection of the discussion topics, presenters and other participants were informed by co-chairs' review (Y. Huang, F. Holguin, L. Segal) of the biomedical literature and prior knowledge of topic relevance and applicability to asthma research. A concerted effort was made to invite experts representing a range of relevant disciplines, including individuals not previously involved in asthma research, to bring broad perspectives. The finalized group of available participants included basic, clinical, and computational scientists with backgrounds in immunology, microbiome, metabolomics, and computational biology. Potential conflicts of interest were reviewed per standard evaluation procedures outlined by ATS.

To help structure discussions during the workshop, each speaker was asked to provide a written summary and identify key gaps in their content areas. These abstracts were circulated to all participants before the workshop. Each twenty-minute presentation was followed by twenty-five minutes of group discussion on the topic. At the end of the workshop, another discussion period was held (60 minutes) to synthesize the discussed material, collate identified gaps and needs, and draft recommendations for future research. Speakers' abstracts were collated for a first draft report (A.J. K., Y.J.H.) and available discussion notes from participants also utilized. All participants had the opportunity to review and edit subsequent drafts of the report.

PRESENTATIONS AND DISCUSSIONS

The workshop began with a brief overview of current evidence for microbiome and metabolic influences on asthma (presenter Yvonne Huang MD). The role of microbiota in shaping early

life immune responses and susceptibility to asthma is well documented, and in some studies, linked to specific metabolite profiles [6,19]. Links between the microbiome, metabolic milieu, and asthma, however, are unlikely static and should be considered as potential modifiers or mediators of asthma throughout the lifespan (**Figure 1**). This includes phenotypes of later-onset disease or of poor treatment response. Moreover, in terms of the microbiome or metabolome, different organ compartments have been studied, which differs also between pediatric and adult studies (e.g., microbiome of the gut versus airways; upper versus lower airway samples; metabolomics of blood, urine, or exhaled breath). In addition to bacteria, viruses and fungi also are important players in the microbiome; however, their role has been better studied in some asthma clinical contexts than others. Metabolism-focused studies have revealed pathways implicated in asthma pathogenesis or specific phenotypes. How these link to concurrent perturbed microbiome or immunologic response patterns remain nascent areas of understanding.

The presentations that followed were focused on specific content areas: (i) **immune and microbial mechanisms of asthma pathogenesis in murine models**, (ii) **the role of microbes in pediatric asthma exacerbations**, (iii) **dysregulated metabolic pathways in asthma associated with obesity**, (iv) **metabolism effects on macrophage function in adipose tissue and the lungs**, (v) **computational approaches to dissect microbiome-metabolite links**; (vi) **potential confounders of microbiome-disease associations in human studies**. Key gaps and challenges identified during the discussions are summarized in **Box 1**.

Immune and microbial mechanisms of asthma pathogenesis in murine models

One of the most critical processes during early life is the development of the immune system. Its maturation is influenced by extrinsic and intrinsic factors, including microbial exposures and

developmental patterns of the gut microbiota especially. Evidence has shown that the microbiome is linked to asthma pathogenesis, but how microbiota and their metabolites shape immune pathways to drive asthma is still not fully understood. Recent evidence has yielded new insight into the role of aberrant immune regulation in giving license to disease development and progression (presenter Talal Chatila MD) [20]. Specifically, an IL-6 Notch4 axis that defines a subpopulation of lung tissue regulatory T (Treg) cells. These cells increase in frequency as a function of disease severity. Modular signaling pathways downstream of Notch4 in Treg cells, including Wnt and Hippo, act to direct Th2 and Th17 tissue inflammation, respectively. Notch4+ Treg cells drive ILC2 activation in allergic airway inflammation by means of a novel pathway involving GDF15 and its receptor GFRAL. The same IL-6 Notch4 module has also emerged as playing a critical role in respiratory viral infections including SARS-CoV-2 and influenza, albeit employing distinct downstream mechanisms centered on restricting Treg cell production of the tissue repair cytokine amphiregulin [21]. How these pathways integrate into the evolution of asthma in response to early life infections, the role of microbiota input in this process and the differential mobilization of these pathways in specific asthma endotypes are all topics of interest.

Severe early life respiratory viral infections, including respiratory syncytial virus (RSV), are associated with persistent immune alterations and asthma development in childhood. While RSV appears to directly alter immune development, studies have shown that other viral infections also alter the gut microbiome, which in turn may shape the systemic immune environment and lungs [22,23]. This was discussed in the context of data from murine studies looking at the effect of gut microbiota modulation on systemic immune and metabolic responses in relation to RSV infection (presenter Nicholas Lukacs, PhD). For example, adult mice orally supplemented with

Lactobacillus johnsonii exhibit decreased airway immunopathology following RSV infection [24]. Interestingly, maternal supplementation with oral *L. johnsonii* resulted in a relatively consistent gut microbiome structure in both mothers and their offspring. Importantly, breastmilk and plasma from *L. johnsonii*-supplemented mothers, and plasma from supplemented offspring, exhibited a depletion in inflammatory metabolites, indicative of the immunoregulatory capacity of the gut microbiome [25]. Cross-fostering studies, whereby pups from one dam are transferred to another dam, have permitted dissection of the effect of maternal *Lactobacillus* supplementation on prenatal and postnatal airway immunity. Prenatal *Lactobacillus* administration led to decreased Th2 cytokines and lung inflammatory cells following RSV infection of the offspring, while postnatal *Lactobacillus* administration diminished goblet cell hypertrophy and mucus production in the lung in response to airway infection. While these and other studies have linked the early life gut microbiome to more severe lung disease, it remains unclear whether this is cause or effect. Also, the role of metabolites as mediators of the microbiome effects remains unknown.

The role of microbes in pediatric asthma exacerbations

Much evidence supports the importance of microbial triggers of asthma exacerbations in children (presenter James Gern MD). Both viral and bacterial pathogens contribute to exacerbations of childhood asthma [26]. Viral infections can compromise the epithelial barrier and induce receptors to enable certain bacteria to attach to host cells, proliferate, and become invasive. Opportunistic pathogens such as *Moraxella catarrhalis*, *Streptococcus pneumoniae*, and *Haemophilus influenzae* are often detected in children but exhibit pathogenic characteristics following a viral infection. More virulent viruses are more likely to be associated with increases in bacterial pathogens [27]. In turn, the combination of a respiratory virus and increased bacterial

pathogen load in airway secretions is associated with increased symptoms and risk for exacerbation [27,28]. Furthermore, allergy and asthma are associated with altered airway microbial composition compared to healthy controls, while a health-associated airway microbial composition, which has been described as commensal-dominated in the upper airways, reduces the risk for illness or exacerbations [29-31]. Of note, for the lower airways, it is less clear what microbiota define a healthy state. Bacteria could contribute to airway obstruction and asthma exacerbations through several mechanisms, including stimulating mucin secretion, damaging airway epithelial cells, and activating airway inflammatory cells to release proteases and increase oxidative stress [32-35]. These new insights into mechanisms of virus-bacterial interactions and exacerbations of asthma could inform novel preventative strategies, such as preventing virus-induced increases in bacterial pathogens or promoting colonization with commensal bacteria that suppress the growth of pathogens.

Dysregulated metabolic pathways in asthma associated with obesity

While mechanisms of asthma involving a variety of cytokine mediators have been extensively studied, growing evidence indicates that cellular metabolism also plays an important role [17,18]. Targeted and non-targeted metabolomic studies (i.e., focused only on a specific class of molecules vs. interrogation of the entire metabolome) in different human biological compartments have shown that biomarkers related to tricarboxylic acid (TCA) cycle, hypoxia response, amino acid metabolism (glutamine, L-arginine) and oxidative stress are all associated with asthma diagnosis or with increased asthma morbidity (presenter Fernando Holguin MD) [11, 36]. Asthmatic and control subjects differ in airway epithelial cell rates of glycolysis and oxidative phosphorylation, and in mitochondrial function and structure [17, 37]. Some of these metabolic differences may occur as a compensatory mechanism. For example, arginase activity

is usually higher among asthmatics, particularly in those with more severe disease [38].

Although traditionally considered just part of the L-arginine metabolic dysregulation observed in asthma, arginase is now known to exert an important role in limiting inflammation [39]. In asthmatic airway epithelial cells increased arginase-2 activity generates ornithine, which then enters the TCA cycle generating metabolic intermediates such as α -ketoglutarate. The latter can reduce inflammation by dampening hypoxia inducible factor (HIF) activation and by generating nitrogen donors to support the formation of L-arginine from L-citrulline [40]. This mechanism links L-arginine metabolism and the TCA cycle as regulators of the inflammatory cascade. However, it is still unknown how these compensatory mechanisms function when additional factors influencing metabolic state are present, such as obesity and/or metabolic syndrome.

Obesity is one of the most significant comorbidities affecting asthma. Patients with asthma who are obese, both children and adults, are less likely to respond to usual therapies and experience more asthma morbidity and worse outcomes [41]. Systemic metabolic dysregulation can directly or indirectly contribute to airways dysfunction. Multiple mechanisms are likely involved, in addition to inflammasome activation [13, 14], such as altered functions of specific immune cells, smooth muscle, or surfactant. A key challenge is understanding how obesity-related systemic metabolic changes directly affect airway inflammation or function. Obese individuals with asthma have lower L-arginine levels, and their airway epithelial cells produce less nitric oxide (NO) due to nitric oxide synthase (NOS) uncoupling. When this occurs, NOS preferentially makes anion super oxide instead of NO. Reduced NO bioavailability can impair bronchodilation while also impacting mitochondrial function. Loss of this NO inhibitory mechanism in obesity, in addition to increased glycolytic rates, is associated with increased maximal mitochondrial

respiration, which in turn increases the production of reactive oxygen species. Indeed, compared to lean counterparts, unstimulated airway epithelial cells from obese asthmatics display increased levels of oxidative and nitrative stress [42]. Ultimately, these processes may adversely influence how the airways handle additional inflammatory, metabolic, or environmental stressors and could partly explain the worse outcomes observed in obese asthma patients. Ongoing gaps include understanding the functional impact of an altered microbiome on the metabolic milieu, or vice versa, and in turn their collective effects on innate and adaptive immune responses in asthma.

Metabolism effects on macrophage function in adipose tissue and the lungs

Mechanistic links between obesity and altered immune responses include well documented alterations in the function of innate immune cells such as macrophages, monocytes, and dendritic cells [43]. Relevant to global immune responses, obesity and dietary factors also are associated with changes in the gut microbiome [44,45], which can further modulate immune development and responses. The study of immunometabolism encompasses both how immune responses are affected by metabolites and nutrients, and how immune cells harness specific metabolic pathways to respond to antigenic and innate stimulants [16]. Myeloid cells are central to the coordination of systemic and tissue specific immunity, and their control and activation by metabolic signals. Specific findings from immunologic studies of adipose tissue were highlighted including niche-specific macrophage properties and functions (presenter Carey Lumeng MD PhD) [46]. For example, tissue-resident alveolar macrophages display a unique metabolic profile, influenced by the concentrations of glucose and lipids in the microenvironment [47]. Outstanding questions and challenges in the field include the mechanisms by which obesity modifies pulmonary and systemic immune responses, the role of microbiome alterations in

obesity on immune responses, the potential to harness nutrient flux and cellular metabolism to control immune responses, and the limitations of animal models to understand links between metabolism and myeloid cell activation.

Computational approaches to dissect microbiome-metabolite links

Studies of the human microbiome often reveal microbiome differences that vary with disease, or that correlate with disease phenotypes, but determining cause versus effect and the specific mechanisms at play are challenging. Dissecting mechanisms that involve metabolite mediators is a critical challenge. Small molecules present in host specimens typically represent a complex mixture of metabolites produced by the host, microbiota, or both; they also may be reflective of environmental exposures such as diet or from inhaled air [48]. There is a need for improved determination of the relative contribution of microbial and host metabolism to the metabolic environment (presenter Catherine Lozupone PhD). This would aid understanding of mediators of host-microbe interactions and their downstream effects. One avenue is to use information in databases on chemical reactions present in microbes and humans to predict which annotated metabolites, in an untargeted metabolome dataset, could have been produced by the host, the microbiome, both, or neither. To support this goal, a recently developed tool called AMON (Analysis of Metabolite Origins using Networks) [49] uses predicted gene sets from the microbiome and the KEGG database to annotate metabolites as to their potential origin. Although this approach and others similar such as MIMOSA [50] are helpful, they only can work on metabolites that are a part of well annotated pathways. The metabolomes of germ-free versus humanized gnotobiotic mice have been compared to assist in identifying small molecules influenced by the presence of microbiota [51]. This approach has the advantage of identifying poorly annotated small molecules but still cannot differentiate between direct

production/consumption by the microbiome versus indirect effects. Another weakness is that not all human microbes of interest may colonize mice used to study this or produce the same metabolites in that context.

Potential confounders of microbiome-disease associations in human studies

Another challenge of studies aiming to dissect microbiome links to disease is the inherent heterogeneity of the human microbiome, and the many endogenous and exogenous factors that modify it. The gut microbiota has been demonstrated to exert strong effects on numerous organ systems in many preclinical disease models [52]. Whether such links translate to humans, and which human gut bacteria mediate these effects, can be difficult to disentangle and thus often poorly understood. The primary method by which human microbiome science has sought to examine these questions has been the cross-sectional association study. Many such studies have found differences in the gut microbiota between cases and controls for prevalent diseases, including asthma. However, low concordance in microbiota results between such studies [53] (e.g., findings based on compositional differences) is a pervasive challenge that limits the capacity to infer causal relationships. The risk of obtaining false positives is exacerbated by interindividual heterogeneity in microbiota composition, probably due to population-wide differences in lifestyle and physiological variables that shape the microbiota. Incomplete knowledge of such variables can stymie accounting for such factors in human cross-sectional or longitudinal studies and contribute to overlooking of confounders.

Recent work [54] utilizing the largest known public database of human gut microbiota profiles aimed to determine the greatest, generalized sources of heterogeneity and their potential impact on disease associations (presenter Ivan Vujkovic-Cvijin PhD). Human lifestyle and physiological

characteristics **were identified** that, if not well-matched between cases and controls, confound microbiota analyses to produce spurious microbial associations with human diseases. Alcohol consumption frequency and bowel movement quality were unexpectedly strong sources of gut microbiota variance that differed in distribution between healthy participants and those with a disease []. For self-reported lung disease diagnoses, BMI was identified as a potential factor that differed between those with or without lung disease, though this was a broad category ('lung disease') and thus other microbiota-associated confounding factors may affect the study of specific lung diseases. In the study by **Vujkovic-Cvijin et al. [54]**, for several prevalent diseases, matching cases and controls for potential confounding variables (e.g., age, sex, BMI, dietary intake, stool quality, others) reduced observed differences in the gut microbiota and the incidence of spurious associations with disease. Thus, **attention to improved matching of subjects** could increase the robustness and reproducibility in resolving members of the gut microbiota truly associated with disease. **Additional tools such as** identification of immunoglobulin-targeted gut bacteria could be leveraged to better understand which specific members of a microbiota elicit pathologic **or homeostatic immune responses [55]**. Future investigations to identify airway-resident microbes that may elicit such immune responses could consider interrogation of anti-**microbiota IgA and/or IgE repertoires within lung mucosal fluids.**

CONCLUSIONS

Ongoing challenges in asthma prevention and management highlight an urgent need for further mechanistic and translational studies to clarify drivers of variation in immune response patterns and clinical trajectories. There was broad consensus that multiple scientific challenges need to be bridged to better understand links between perturbed microbiome and metabolic states, and their collective impact on airway immune cell function and asthma pathophysiology. Key research

questions and gaps identified during the workshop are highlighted in **Box 1**. Recommendations for future research focus are presented in **Box 2**.

Several overarching conceptual questions were posed. Associative microbiome or metabolomic findings from human studies raise the perennial question of cause versus effect. It is inevitable, however, that multi-directional interactions are at play in biological systems. Thus, channeling efforts towards better understanding mechanisms of interaction between specific components in a system or niche could be more informative. For example, it is important to understand how microbiota (or a specific set of microbial functions) shape the airway metabolic milieu to promote lung immune responses to infectious agents or allergen immune tolerance. Also critical is understanding how intra- and extra-cellular metabolic conditions affect the function of specific immune cells. Such mechanistic insights could then support the development of interventions that are microbially and metabolically informed.

Hurdles remain in the technical and translational realm for applied human studies. Untargeted metabolomics approaches are hampered by incomplete databases that render identification of metabolites a major challenge. More knowledge is needed regarding which metabolites can be produced by specific microbes or are co-metabolized with the host, including real-time functional studies using *in vitro* and *in vivo* model systems. Multi-dimensional data analysis can be computationally challenging, coupled with a need for further statistical method development to accommodate data characteristics. Moreover, variables representing important host characteristics need to be integrated into such analyses to mitigate misinterpretation or confounding. Compared to the gut microbiome, the role of confounding factors in associative studies of the lower airway microbiome is less understood or appreciated, with exception of antibiotic exposures. Moreover, whether functions of lower airway microbiota, not just their

composition, vary in relation to factors unrelated to asthma is unknown. Finally, cross-study comparisons can be challenging due to differences in study design, technical platforms, and data analysis strategies. This can be addressed by careful and upfront study designs to yield maximally interpretable data and mechanism-oriented insights. Considerations include longitudinal and/or interventional studies, and importantly, more precise definition of asthma phenotypes, where applicable, to compare and interpret molecular, microbial, and immunologic findings. It could also be useful to include alternative or intermediate outcome measures that capture these biological readouts, to examine potential mechanistic links.

In conclusion, findings from this workshop highlighted recognized challenges but also exciting avenues for further development, that will lay the foundations to better understand the impact of perturbed microbiome and metabolic responses in asthma pathogenesis and outcomes. More attention to these aspects as potential proximal drivers of immunologic and clinical heterogeneity in asthma may lead to new and more precise strategies to alleviate asthma burden.

This workshop report was developed by an ad hoc subcommittee of the ATS and NIAID.

Yvonne J. Huang MD (Chair/speaker; lead organizer, writing/editing of report)

Fernando Holguin MD (Co-Chair/speaker, writing/editing of report)

Leopoldo N. Segal MD (Co-Chair; review/editing of report)

Talal A. Chatila MD (speaker; writing/editing of report)

Anne E. Dixon BM BCh (participant; review/editing of report)

James E. Gern MD (speaker; writing/editing of report)

Ariangela J. Kozik PhD (participant; writing/editing of report)

Catherine Lozupone PhD (speaker; writing/editing of report)

Nicholas Lukacs PhD (speaker; writing/editing of report)

Carey Lumeng MD PhD (speaker; writing/editing of report)

Philip L. Molyneaux MD PhD (participant; review/editing of report)

Nichole Reisdorph PhD (participant; review/editing of report)

Ivan Vujkovic-Cvijin PhD (speaker; writing/editing of report)

Alkis Togias MD (participant; review/editing of report)

References.

1. Johnson CC, Chandran A, Havstad S, Li X, McEvoy CT, Ownby DR, et al. US Childhood Asthma Incidence Rate Patterns From the ECHO Consortium to Identify High-risk Groups for Primary Prevention. *JAMA Pediatr.* 2021 Sep 1;175(9):919–27.
2. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. *Lancet.* 2018 Feb 24;391(10122):783–800.
3. Hudey SN, Ledford DK, Cardet JC. Mechanisms of non-type 2 asthma. *Curr Opin Immunol.* 2020 Oct;66:123–8.
4. Lambrecht BN, Hammad H, Fahy JV. The Cytokines of Asthma. *Immunity.* 2019 Apr 16;50(4):975–91.
5. Budden KF, Shukla SD, Rehman SF, Bowerman KL, Keely S, Hugenholtz P, Armstrong-James DPH, Adcock IM, Chotirmall SH, Chung KF, Hansbro PM. Functional effects of the microbiota in chronic respiratory disease. *Lancet Respir Med.* 2019 Oct;7(10):907-920.
6. Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosch D, et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. *Nat Med.* 2016;22(10):1187–91.
7. Chiu C-Y, Chou H-C, Chang L-C, Fan W-L, Dinh MCV, Kuo Y-L, et al. Integration of metagenomics-metabolomics reveals specific signatures and functions of airway microbiota in mite-sensitized childhood asthma. *Allergy.* 2020 Nov;75(11):2846–57.
8. Teo SM, Tang HHF, Mok D, Judd LM, Watts SC, Pham K, et al. Airway Microbiota Dynamics Uncover a Critical Window for Interplay of Pathogenic Bacteria and Allergy in Childhood Respiratory Disease. *Cell Host Microbe.* 2018 12;24(3):341-352.e5.

9. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nat Med*. 2014 Feb;20(2):159–66.
10. Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. *J Allergy Clin Immunol*. 2017 Jul;140(1):63–75.
11. Kelly RS, Dahlin A, McGeachie MJ, Qiu W, Sordillo J, Wan ES, et al. Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic. *Chest*. 2017 Feb;151(2):262–77.
12. Dixon AE, Holguin F. Diet and Metabolism in the Evolution of Asthma and Obesity. *Clin Chest Med*. 2019;40(1):97–106.
13. Williams EJ, Negewo NA, Baines KJ. Role of the NLRP3 inflammasome in asthma: Relationship with neutrophilic inflammation, obesity, and therapeutic options. *J Allergy Clin Immunol*. 2021 Jun;147(6):2060–2.
14. Wood LG, Li Q, Scott HA, Rutting S, Berthon BS, Gibson PG, et al. Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients. *J Allergy Clin Immunol*. 2019;143(1):305–15.
15. Pinkerton JW, Kim RY, Brown AC, Rae BE, Donovan C, Mayall JR, et al. Relationship between type 2 cytokine and inflammasome responses in obesity-associated asthma. *J Allergy Clin Immunol*. 2022 Apr;149(4):1270–80.
16. Makowski L, Chaib M, Rathmell JC. Immunometabolism: From basic mechanisms to translation. *Immunol Rev*. 2020 May;295(1):5–14.

17. Michaeloudes C, Bhavsar PK, Mumby S, Xu B, Hui CKM, Chung KF, et al. Role of Metabolic Reprogramming in Pulmonary Innate Immunity and Its Impact on Lung Diseases. *J Innate Immun*. 2020;12(1):31–46.
18. Runtsch MC, Angiari S, Hooftman A, Wadhwa R, Zhang Y, Zheng Y, et al. Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages. *Cell Metab*. 2022 Mar 1;34(3):487-501.e8.
19. Rago D, Pedersen C-ET, Huang M, Kelly RS, Gürdeniz G, Brustad N, et al. Characteristics and Mechanisms of a Sphingolipid-associated Childhood Asthma Endotype. *Am J Respir Crit Care Med*. 2021 Apr 1;203(7):853–63.
20. Harb H, Stephen-Victor E, Crestani E, Benamar M, Massoud A, Cui Y, et al. A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma. *Nat Immunol*. 2020 Nov;21(11):1359–70.
21. Harb H, Benamar M, Lai PS, Contini P, Griffith JW, Crestani E, et al. Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. *Immunity*. 2021 Jun 8;54(6):1186-1199.e7.
22. Sencio V, Machado MG, Trottein F. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes. *Mucosal Immunol*. 2021 Mar;14(2):296–304.
23. Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The Role of Lung and Gut Microbiota in the Pathology of Asthma. *Immunity*. 2020 Feb 18;52(2):241–55.
24. Fonseca W, Lucey K, Jang S, Fujimura KE, Rasky A, Ting H-A, et al. *Lactobacillus johnsonii* supplementation attenuates respiratory viral infection via metabolic reprogramming and immune cell modulation. *Mucosal Immunol*. 2017 Nov;10(6):1569–80.

25. Fonseca W, Malinczak C-A, Fujimura K, Li D, McCauley K, Li J, et al. Maternal gut microbiome regulates immunity to RSV infection in offspring. *J Exp Med*. 2021 Nov 1;218(11):e20210235.
26. Bisgaard H, Hermansen MN, Bønnelykke K, Stokholm J, Baty F, Skytt NL, et al. Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study. *BMJ*. 2010 Oct 4;341:c4978.
27. Bashir H, Grindle K, Vrtis R, Vang F, Kang T, Salazar L, et al. Association of rhinovirus species with common cold and asthma symptoms and bacterial pathogens. *J Allergy Clin Immunol*. 2018 Feb;141(2):822-824.e9.
28. Kloefer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, et al. Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. *J Allergy Clin Immunol*. 2014 May;133(5):1301–7, 1307.e1-3.
29. Kloefer KM, Sarsani VK, Poroyko V, Lee WM, Pappas TE, Kang T, et al. Community-acquired rhinovirus infection is associated with changes in the airway microbiome. *J Allergy Clin Immunol*. 2017 Jul;140(1):312-315.e8.
30. McCauley K, Durack J, Valladares R, Fadrosch DW, Lin DL, Calatroni A, et al. Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma. *J Allergy Clin Immunol*. 2019 Nov;144(5):1187–97.
31. Zhou Y, Jackson D, Bacharier LB, Mauger D, Boushey H, Castro M, et al. The upper-airway microbiota and loss of asthma control among asthmatic children. *Nat Commun*. 2019 16;10(1):5714.

32. Alnahas S, Hagner S, Raifer H, Kilic A, Gasteiger G, Mutters R, et al. IL-17 and TNF- α Are Key Mediators of *Moraxella catarrhalis* Triggered Exacerbation of Allergic Airway Inflammation. *Front Immunol*. 2017;8:1562.
33. Heinrich A, Heyl KA, Klaile E, Müller MM, Klassert TE, Wiessner A, et al. *Moraxella catarrhalis* induces CEACAM3-Syk-CARD9-dependent activation of human granulocytes. *Cell Microbiol*. 2016 Nov;18(11):1570–82.
34. Dohrman A, Miyata S, Gallup M, Li JD, Chapelin C, Coste A, et al. Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria. *Biochim Biophys Acta*. 1998 Apr 28;1406(3):251–9.
35. Zahlten J, Kim Y-J, Doehn J-M, Pribyl T, Hocke AC, García P, et al. *Streptococcus pneumoniae*-Induced Oxidative Stress in Lung Epithelial Cells Depends on Pneumococcal Autolysis and Is Reversible by Resveratrol. *J Infect Dis*. 2015 Jun 1;211(11):1822–30.
36. Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. *J Allergy Clin Immunol*. 2020 Oct;146(4):685–93.
37. Bhatraju NK, Agrawal A. Mitochondrial Dysfunction Linking Obesity and Asthma. *Ann Am Thorac Soc*. 2017 Nov;14(Supplement_5):S368–73.
38. Yamamoto M, Tochino Y, Chibana K, Trudeau JB, Holguin F, Wenzel SE. Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation. *Clin Exp Allergy*. 2012 May;42(5):760–8.
39. Grasemann H, Holguin F. Oxidative stress and obesity-related asthma. *Paediatr Respir Rev*. 2021 Mar;37:18–21.

40. Xu W, Ghosh S, Comhair SAA, Asosingh K, Janocha AJ, Mavrakakis DA, et al. Increased mitochondrial arginine metabolism supports bioenergetics in asthma. *J Clin Invest*. 2016 Jul 1;126(7):2465–81.
41. Peters U, Dixon AE, Forno E. Obesity and asthma. *J Allergy Clin Immunol*. 2018 Apr;141(4):1169–79.
42. Winnica D, Corey C, Mullett S, Reynolds M, Hill G, Wendell S, et al. Bioenergetic Differences in the Airway Epithelium of Lean Versus Obese Asthmatics Are Driven by Nitric Oxide and Reflected in Circulating Platelets. *Antioxid Redox Signal*. 2019 Oct 1;31(10):673–86.
43. Mancuso P. Obesity and lung inflammation. *J Appl Physiol* (1985). 2010 Mar;108(3):722–8.
44. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas M-E. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. *Genome Med*. 2016 Apr 20;8(1):42.
45. Singh RK, Chang H-W, Yan D, Lee KM, Ucmak D, Wong K, et al. Influence of diet on the gut microbiome and implications for human health. *J Transl Med*. 2017 Apr 8;15(1):73.
46. Russo L, Lumeng CN. Properties and functions of adipose tissue macrophages in obesity. *Immunology*. 2018 Dec;155(4):407–17.
47. Woods PS, Kimmig LM, Meliton AY, Sun KA, Tian Y, O’Leary EM, et al. Tissue-Resident Alveolar Macrophages Do Not Rely on Glycolysis for LPS-induced Inflammation. *Am J Respir Cell Mol Biol*. 2020 Feb;62(2):243–55.
48. Shaffer M, Armstrong AJS, Phelan VV, Reisdorph N, Lozupone CA. Microbiome and metabolome data integration provides insight into health and disease. *Transl Res*. 2017 Nov;189:51–64.

49. Shaffer M, Thurimella K, Quinn K, Doenges K, Zhang X, Bokatzian S, et al. AMON: annotation of metabolite origins via networks to integrate microbiome and metabolome data. *BMC Bioinformatics*. 2019 Nov 28;20(1):614.
50. Noecker C, Eng A, Srinivasan S, Theriot CM, Young VB, Jansson JK, et al. Metabolic Model-Based Integration of Microbiome Taxonomic and Metabolomic Profiles Elucidates Mechanistic Links between Ecological and Metabolic Variation. *mSystems*. 2016 Feb;1(1):e00013-15.
51. Marcobal A, Kashyap PC, Nelson TA, Aronov PA, Donia MS, Spormann A, et al. A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. *ISME J*. 2013 Oct;7(10):1933–43.
52. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol*. 2021 Jan;19(1):55–71.
53. Abdel-Aziz MI, Vijverberg SJH, Neerincx AH, Kraneveld AD, Maitland-van der Zee AH. The crosstalk between microbiome and asthma: Exploring associations and challenges. *Clin Exp Allergy*. 2019 Aug;49(8):1067–86.
54. Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y. Host variables confound gut microbiota studies of human disease. *Nature*. 2020 Nov;587(7834):448–54.
55. Weis AM, Round JL. Microbiota-antibody interactions that regulate gut homeostasis. *Cell Host Microbe*. 2021 Mar 10;29(3):334-346.




Figure 1. Shifts in microbiome functions and metabolic states have the capacity to shape immune responses and asthma outcomes across the lifespan. Created with BioRender.com.

Box 1. Major gaps and challenges for understanding the intersecting effects of microbiota, metabolism, and immune responses on asthma pathogenesis and phenotypes.

Conceptual	• Does the microbiome promote changes in immunity through particular metabolite production profiles? • What are the mechanisms that program lung immune responses to infectious agents and immune tolerance to allergens, and what is the contribution of microbiota (bacteria, fungi, and viruses) of the airways vs the gut? • What are the contributions of direct (e.g. diet) and indirect disrupted metabolism to altered function of myeloid cells impacting asthma? • How do commensal bacteria help to maintain normal airway physiology? • Does an altered microbiome promote asthma in an already predisposed host, or does it actually induce the disease? • Can appropriate immune responses to infectious agents or immune tolerance to allergens be re-established in the chronically inflamed airways? If so, how?
Technical	• Untargeted metabolomics approaches limited by incomplete databases and unreliable identification of metabolites • Links between microbiota and metabolites - gaps in knowledge regarding what microbiota directly produce, metabolize, or co-metabolize with hosts • Need for standardized and robust methods for integrating and analyzing multi-dimensional data; sample size requirements • Capturing and evaluating potential confounding variables that can influence microbial or metabolic associations with disease
Translational	• What aspects of the maternal microbiome contribute to infant immune functions and how does this compare to the role of developmental changes of the infant microbiome during early childhood? In utero or post-natal? • What aspects of the airway microbiome shape airway immune response patterns during early life and how do these differ between asthma phenotypes? • What is the relative contribution of changes in local (airway milieu) vs. systemic metabolism on airway immune cell functions and pathophysiology in asthma? • Can the airway microbiome be modified to promote commensal bacteria or revert dysbiosis associated with asthma?

Box 2. Suggestions for Future Research.

Basic, Translational	• Studies of host immune response in relation to metabolic and microbiome profiles • Studies of the nutrient environment in the context of allergic inflammation • Studies of the intersecting mechanisms involving gut microbiota, formation of specific metabolic products, and effects on airway immune responses in asthma • Studies to understand how airway commensals and pathogens interact with mucosal immunity to modify airway function in asthma • Studies of microbiome alterations, metabolism and immune pathway interactions in obesity and asthma
Technical	• Expanded sample collections from different biological compartments to enable systems-based analyses • Benchmarking studies to define concordance between measured relative levels of metabolites and actual production • Generation and integration of multi-omic data to dissect the mechanisms of microbial or metabolic effects on immune responses • Further development of statistical approaches for multi-dimensional data analysis
Clinical	• Improved study designs that can support more robust analyses or exploration of mechanisms. Considerations, ideas include: ○ Longitudinal studies to increase analytical robustness and capture time effects ○ Larger sample sizes to capture sub-phenotypes/endotypes and interactions ○ Studies of the developmental trajectory of the airway microbiome in healthy vs. asthmatic children ○ Studies to examine microbial, metabolic and immunologic interactions in asthma during adolescent to adult transition with focus on sex differences and on obesity ○ More precise definition of phenotypes and sub-phenotypes to better interpret comparative findings (e.g. obesity-induced vs. obesity-complicated asthma; adult-onset vs. late-onset) ○ Timing of sample collections to enable comparisons at baseline and follow up post-therapeutic intervention. ○ Thorough determination of endogenous and exogenous variables that may influence or confound microbial or metabolism-related associations with asthma ○ Promotion of inclusion of mechanistic outcomes in phase 2 clinical trials ○ Development of strategies for collection and appropriate storage of samples that can be used for immune marker, microbiome and metabolome profiling in clinical trials and observational studies

**Microbiome, Metabolism, and Immunoregulation of Asthma:
An American Thoracic Society and National Institute of Allergy and Infectious Diseases
Joint Workshop report**

Ariangela J. Kozik PhD¹, Fernando Holguin MD², Leopoldo N. Segal MD (ORCID 0000-0003-3559-9431)³, Talal A. Chatila MD⁴, Anne E. Dixon BM BCh⁵, James E. Gern MD (ORCID 0000-0002-6667-4708)⁶, Catherine Lozupone PhD⁷, Nicholas Lukacs PhD⁸, Carey Lumeng MD PhD^{9,10}, Philip L Molyneaux MD PhD (ORCID 0000-0003-1301-8800)¹¹, Nichole Reisdorph PhD¹², Ivan Vujkovic-Cvijin PhD¹³, Alkis Togias MD (ORCID 0000-0001-9009-5717)¹⁴, and Yvonne J. Huang MD^{1,15} (ORCID 0000-0002-7497-6597)* on behalf of the American Thoracic Society and the National Institute of Allergy and Infectious Diseases

¹ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor

² Division of Pulmonary and Critical Care Medicine, University of Colorado

³ Division of Pulmonary, Critical Care Medicine, and Sleep Medicine, New York University School of Medicine

⁴ Division of Immunology, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA

⁵ Division of Pulmonary and Critical Care Medicine, University of Vermont, Burlington

⁶ Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of Wisconsin, Madison, WI

⁷ Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Campus

⁸ Department of Pathology, University of Michigan, Ann Arbor

⁹ Division of Pediatric Pulmonology, Department of Pediatrics

¹⁰ Department of Molecular and Integrative Physiology; University of Michigan, Ann Arbor

¹¹ National Heart and Lung Institute, Imperial College London, London, United Kingdom

¹² Department of Pharmaceutical Sciences, University of Colorado Anschutz Campus

¹³ Metaorganism Immunity Section, Laboratory of Immune Systems Biology, NIAID/NIH, Bethesda, MD

¹⁴ Allergy, Asthma and Airway Biology Branch; NIAID/NIH, Bethesda, MD

¹⁵ Department of Microbiology and Immunology, University of Michigan, Ann Arbor

***Corresponding Author:**

Yvonne J. Huang MD

6301 Medical Science Research Building-3,

1150 W. Medical Center Drive

Ann Arbor, MI 48109.

Email: yvjhuang@umich.edu

Phone: (734) 936-5201

Fax: (734) 764-4556

Word count: 3,756

Key Words: microbiota, metabolites, phenotype, obesity, translational studies

Disclaimer: Dr. Togias' co-authorship and the NIAID name in the title of this publication do not constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, or any agency of the US government.

For Review Only

ABSTRACT

This report presents the proceedings from a workshop entitled “Microbiome, Metabolism and Immunoregulation of Asthma” that was held virtually May 13th-14th, 2021. The workshop was jointly sponsored by the American Thoracic Society (Assembly on Allergy, Immunology, and Inflammation) and the National Institute of Allergy and Infectious Diseases. It convened an inter-disciplinary group of experts with backgrounds in asthma immunology, microbiome science, metabolomics, computational biology, and translational pulmonary research. The main purpose was to identify key scientific gaps and needs to further advance research on microbial and metabolic mechanisms that may contribute to variable immune responses and disease heterogeneity in asthma. Discussions were structured around several topics that included: (1) immune and microbial mechanisms of asthma pathogenesis in murine models; (2) the role of microbes in pediatric asthma exacerbations; (3) dysregulated metabolic pathways in asthma associated with obesity; (4) metabolism effects on macrophage function in adipose tissue and the lungs; (5) computational approaches to dissect microbiome-metabolite links, and (6) potential confounders of microbiome-disease associations in human studies. This report summarizes the major points of discussion which included identification of specific knowledge gaps, challenges, and suggested directions for future research. These include questions surrounding mechanisms by which microbiota and metabolites shape host health versus allergic or asthmatic state, direct and indirect influences of other biological factors, exposures and comorbidities on these interactions, and ongoing technical and analytical gaps for clinical translation.

TABLE OF CONTENTS

Introduction

Methods

Presentations and Discussions

Immune and microbial mechanisms of asthma pathogenesis in murine models

The role of microbes in pediatric asthma exacerbations

Dysregulated metabolic pathways in asthma associated with obesity

Metabolism effects on macrophage function in adipose tissue and the lungs

Computational approaches to dissect microbiome-metabolite links

Potential confounders of microbiome-disease associations in human studies.

Conclusions

OVERVIEW

Multiple scientific directions must be bridged to better understand links between perturbed microbiome and metabolic states, airway immune activity, and asthma pathophysiology. Further knowledge of functional mechanisms through which microbiota and metabolites regulate host health or shape the development and persistence of asthma is still needed. This interdisciplinary workshop was formed to identify the challenges and needs that currently hamper progress in these areas. Key points include:

- Microbiome functions and metabolic states can shape immune responses and asthma outcomes across the lifespan.
- Better understanding of how microbiota and metabolites together regulate or alter immune functions is needed, including their effects on asthma pathophysiology. Key conceptual questions are described in **Box 1**.
- Improved clinical study designs, technical platforms/resources and integrated data analysis methods will help drive further advancement in this field. Specific recommendations for future research are described in **Box 2**.

INTRODUCTION

Asthma is a complex chronic airway disease that affects patients across the lifespan. Its manifestations in early life, adolescence, and adulthood share common threads, but are otherwise heterogenous, suggesting multiple underlying etiologies. Likewise, divergent clinical outcomes highlight the needs for a more precise understanding of asthma pathophysiology. The foundations for allergy-related asthma and its manifestations are often set in early life and childhood. However, sex-related trends in asthma prevalence shift after puberty [1]. Many phenotypes of adult asthma have been described, but the mechanisms for most remain incompletely understood [2]. Asthma characterized by predominant type 2 (T2) inflammation is the best understood endophenotype with targeted therapies available. Yet, sub-optimal treatment responses are not uncommon. Additionally, a large proportion of patients have asthma without significant T2 inflammation [3] or display a mix of T2 and non-T2 inflammation, for which no precise therapies or biomarkers currently exist. These include later-onset asthma phenotypes such as obesity-associated disease.

Differences in airway immune responses contribute to variation between asthma patients in disease phenotypes and treatment response [4], but the pathobiological drivers are not fully understood. Incomplete or lack of expected treatment responses, even in those receiving biologics that target specific immune components, implicate additional factors and adjunct pathways of disease activation. Recent research has yielded cumulative evidence highlighting important links between asthma, altered microbiome characteristics (gut and airways), and perturbed metabolic states including microbial-derived mediators [5-10]. Systemic markers of inflammation, inflammasome activation, and metabolic dysregulation also are prominent in some

asthma patients and associate with more severe disease [11-15]. In parallel, advances in the immunometabolism field have highlighted that effector properties of innate and adaptive immune cells are modulated by their environment [16]. Cellular metabolism could be influenced by the presence of an altered microbiome and extracellular metabolic milieu. The impact of such on the activation and regulation of innate and adaptive immune functions implicated in asthma could be significant based on recent growing evidence [17,18], but human translation of current knowledge remains nascent.

To address this topic, a workshop jointly sponsored by the American Thoracic Society (ATS) and the National Institute of Allergy and Infectious Diseases (NIAID) was held virtually May 13-14, 2021. The overall purpose was to identify challenges and needs that currently hamper progress in understanding how altered microbiome and metabolic states intersect to shape immune responses and disease phenotype in asthma. The participants represented an interdisciplinary group of scientists with expertise across these topics, including from outside the asthma field. This report summarizes these discussions. Key gaps and challenges identified by the panel, along with suggested future research directions, are summarized in Boxes 1 and 2.

METHODS

The topic of this workshop was conceived during informal discussions among members of the ATS Assembly on Allergy, Immunology, and Inflammation and further discussed with the NIAID Allergy, Asthma, and Airway Biology Branch (Alkis Togias MD) to determine interest in convening a jointly sponsored workshop. A proposal was then submitted by Yvonne Huang MD (workshop chair) to the ATS for formal approval of the project. The workshop originally was to be held in-person at the time of the ATS International Conference in 2020 but delayed due to the

interceding SARS-CoV-2 pandemic. It was subsequently re-organized for 2021 and conducted virtually over two consecutive days, following the same originally approved meeting structure and participant roster.

Selection of the discussion topics, presenters and other participants were informed by co-chairs' review (Y. Huang, F. Holguin, L. Segal) of the biomedical literature and prior knowledge of topic relevance and applicability to asthma research. A concerted effort was made to invite experts representing a range of relevant disciplines, including individuals not previously involved in asthma research, to bring broad perspectives. The finalized group of available participants included basic, clinical, and computational scientists with backgrounds in immunology, microbiome, metabolomics, and computational biology. Potential conflicts of interest were reviewed per standard evaluation procedures outlined by ATS.

To help structure discussions during the workshop, each speaker was asked to provide a written summary and identify key gaps in their content areas. These abstracts were circulated to all participants before the workshop. Each twenty-minute presentation was followed by twenty-five minutes of group discussion on the topic. At the end of the workshop, another discussion period was held (60 minutes) to synthesize the discussed material, collate identified gaps and needs, and draft recommendations for future research. Speakers' abstracts were collated for a first draft report (A.J. K., Y.J.H.) and available discussion notes from participants also utilized. All participants had the opportunity to review and edit subsequent drafts of the report.

PRESENTATIONS AND DISCUSSIONS

The workshop began with a brief overview of current evidence for microbiome and metabolic influences on asthma (presenter Yvonne Huang MD). The role of microbiota in shaping early

life immune responses and susceptibility to asthma is well documented, and in some studies, linked to specific metabolite profiles [6,19]. Links between the microbiome, metabolic milieu, and asthma, however, are unlikely static and should be considered as potential modifiers or mediators of asthma throughout the lifespan (**Figure 1**). This includes phenotypes of later-onset disease or of poor treatment response. Moreover, in terms of the microbiome or metabolome, different organ compartments have been studied, which differs also between pediatric and adult studies (e.g., microbiome of the gut versus airways; upper versus lower airway samples; metabolomics of blood, urine, or exhaled breath). In addition to bacteria, viruses and fungi also are important players in the microbiome; however, their role has been better studied in some asthma clinical contexts than others. Metabolism-focused studies have revealed pathways implicated in asthma pathogenesis or specific phenotypes. How these link to concurrent perturbed microbiome or immunologic response patterns remain nascent areas of understanding.

The presentations that followed were focused on specific content areas: (i) immune and microbial mechanisms of asthma pathogenesis in murine models, (ii) the role of microbes in pediatric asthma exacerbations, (iii) dysregulated metabolic pathways in asthma associated with obesity, (iv) metabolism effects on macrophage function in adipose tissue and the lungs, (v) computational approaches to dissect microbiome-metabolite links; (vi) potential confounders of microbiome-disease associations in human studies. Key gaps and challenges identified during the discussions are summarized in **Box 1**.

Immune and microbial mechanisms of asthma pathogenesis in murine models

One of the most critical processes during early life is the development of the immune system. Its maturation is influenced by extrinsic and intrinsic factors, including microbial exposures and

developmental patterns of the gut microbiota especially. Evidence has shown that the microbiome is linked to asthma pathogenesis, but how microbiota and their metabolites shape immune pathways to drive asthma is still not fully understood. Recent evidence has yielded new insight into the role of aberrant immune regulation in giving license to disease development and progression (presenter Talal Chatila MD) [20]. Specifically, an IL-6 Notch4 axis that defines a subpopulation of lung tissue regulatory T (Treg) cells. These cells increase in frequency as a function of disease severity. Modular signaling pathways downstream of Notch4 in Treg cells, including Wnt and Hippo, act to direct Th2 and Th17 tissue inflammation, respectively. Notch4+ Treg cells drive ILC2 activation in allergic airway inflammation by means of a novel pathway involving GDF15 and its receptor GFRAL. The same IL-6 Notch4 module has also emerged as playing a critical role in respiratory viral infections including SARS-CoV-2 and influenza, albeit employing distinct downstream mechanisms centered on restricting Treg cell production of the tissue repair cytokine amphiregulin [21]. How these pathways integrate into the evolution of asthma in response to early life infections, the role of microbiota input in this process and the differential mobilization of these pathways in specific asthma endotypes are all topics of interest.

Severe early life respiratory viral infections, including respiratory syncytial virus (RSV), are associated with persistent immune alterations and asthma development in childhood. While RSV appears to directly alter immune development, studies have shown that other viral infections also alter the gut microbiome, which in turn may shape the systemic immune environment and lungs [22,23]. This was discussed in the context of data from murine studies looking at the effect of gut microbiota modulation on systemic immune and metabolic responses in relation to RSV infection (presenter Nicholas Lukacs, PhD). For example, adult mice orally supplemented with

Lactobacillus johnsonii exhibit decreased airway immunopathology following RSV infection [24]. Interestingly, maternal supplementation with oral *L. johnsonii* resulted in a relatively consistent gut microbiome structure in both mothers and their offspring. Importantly, breastmilk and plasma from *L. johnsonii*-supplemented mothers, and plasma from supplemented offspring, exhibited a depletion in inflammatory metabolites, indicative of the immunoregulatory capacity of the gut microbiome [25]. Cross-fostering studies, whereby pups from one dam are transferred to another dam, have permitted dissection of the effect of maternal *Lactobacillus* supplementation on prenatal and postnatal airway immunity. Prenatal *Lactobacillus* administration led to decreased Th2 cytokines and lung inflammatory cells following RSV infection of the offspring, while postnatal *Lactobacillus* administration diminished goblet cell hypertrophy and mucus production in the lung in response to airway infection. While these and other studies have linked the early life gut microbiome to more severe lung disease, it remains unclear whether this is cause or effect. Also, the role of metabolites as mediators of the microbiome effects remains unknown.

The role of microbes in pediatric asthma exacerbations

Much evidence supports the importance of microbial triggers of asthma exacerbations in children (presenter James Gern MD). Both viral and bacterial pathogens contribute to exacerbations of childhood asthma [26]. Viral infections can compromise the epithelial barrier and induce receptors to enable certain bacteria to attach to host cells, proliferate, and become invasive. Opportunistic pathogens such as *Moraxella catarrhalis*, *Streptococcus pneumoniae*, and *Haemophilus influenzae* are often detected in children but exhibit pathogenic characteristics following a viral infection. More virulent viruses are more likely to be associated with increases in bacterial pathogens [27]. In turn, the combination of a respiratory virus and increased bacterial

pathogen load in airway secretions is associated with increased symptoms and risk for exacerbation [27,28]. Furthermore, allergy and asthma are associated with altered airway microbial composition compared to healthy controls, while a health-associated airway microbial composition, which has been described as commensal-dominated in the upper airways, reduces the risk for illness or exacerbations [29-31]. Of note, for the lower airways, it is less clear what microbiota define a healthy state. Bacteria could contribute to airway obstruction and asthma exacerbations through several mechanisms, including stimulating mucin secretion, damaging airway epithelial cells, and activating airway inflammatory cells to release proteases and increase oxidative stress [32-35]. These new insights into mechanisms of virus-bacterial interactions and exacerbations of asthma could inform novel preventative strategies, such as preventing virus-induced increases in bacterial pathogens or promoting colonization with commensal bacteria that suppress the growth of pathogens.

Dysregulated metabolic pathways in asthma associated with obesity

While mechanisms of asthma involving a variety of cytokine mediators have been extensively studied, growing evidence indicates that cellular metabolism also plays an important role [17,18]. Targeted and non-targeted metabolomic studies (i.e., focused only on a specific class of molecules vs. interrogation of the entire metabolome) in different human biological compartments have shown that biomarkers related to tricarboxylic acid (TCA) cycle, hypoxia response, amino acid metabolism (glutamine, L-arginine) and oxidative stress are all associated with asthma diagnosis or with increased asthma morbidity (presenter Fernando Holguin MD) [11, 36]. Asthmatic and control subjects differ in airway epithelial cell rates of glycolysis and oxidative phosphorylation, and in mitochondrial function and structure [17, 37]. Some of these metabolic differences may occur as a compensatory mechanism. For example, arginase activity

is usually higher among asthmatics, particularly in those with more severe disease [38].

Although traditionally considered just part of the L-arginine metabolic dysregulation observed in asthma, arginase is now known to exert an important role in limiting inflammation [39]. In asthmatic airway epithelial cells increased arginase-2 activity generates ornithine, which then enters the TCA cycle generating metabolic intermediates such as α -ketoglutarate. The latter can reduce inflammation by dampening hypoxia inducible factor (HIF) activation and by generating nitrogen donors to support the formation of L-arginine from L-citrulline [40]. This mechanism links L-arginine metabolism and the TCA cycle as regulators of the inflammatory cascade. However, it is still unknown how these compensatory mechanisms function when additional factors influencing metabolic state are present, such as obesity and/or metabolic syndrome.

Obesity is one of the most significant comorbidities affecting asthma. Patients with asthma who are obese, both children and adults, are less likely to respond to usual therapies and experience more asthma morbidity and worse outcomes [41]. Systemic metabolic dysregulation can directly or indirectly contribute to airways dysfunction. Multiple mechanisms are likely involved, in addition to inflammasome activation [13, 14], such as altered functions of specific immune cells, smooth muscle, or surfactant. A key challenge is understanding how obesity-related systemic metabolic changes directly affect airway inflammation or function. Obese individuals with asthma have lower L-arginine levels, and their airway epithelial cells produce less nitric oxide (NO) due to nitric oxide synthase (NOS) uncoupling. When this occurs, NOS preferentially makes anion super oxide instead of NO. Reduced NO bioavailability can impair bronchodilation while also impacting mitochondrial function. Loss of this NO inhibitory mechanism in obesity, in addition to increased glycolytic rates, is associated with increased maximal mitochondrial

respiration, which in turn increases the production of reactive oxygen species. Indeed, compared to lean counterparts, unstimulated airway epithelial cells from obese asthmatics display increased levels of oxidative and nitrative stress [42]. Ultimately, these processes may adversely influence how the airways handle additional inflammatory, metabolic, or environmental stressors and could partly explain the worse outcomes observed in obese asthma patients. Ongoing gaps include understanding the functional impact of an altered microbiome on the metabolic milieu, or vice versa, and in turn their collective effects on innate and adaptive immune responses in asthma.

Metabolism effects on macrophage function in adipose tissue and the lungs

Mechanistic links between obesity and altered immune responses include well documented alterations in the function of innate immune cells such as macrophages, monocytes, and dendritic cells [43]. Relevant to global immune responses, obesity and dietary factors also are associated with changes in the gut microbiome [44,45], which can further modulate immune development and responses. The study of immunometabolism encompasses both how immune responses are affected by metabolites and nutrients, and how immune cells harness specific metabolic pathways to respond to antigenic and innate stimulants [16]. Myeloid cells are central to the coordination of systemic and tissue specific immunity, and their control and activation by metabolic signals. Specific findings from immunologic studies of adipose tissue were highlighted including niche-specific macrophage properties and functions (presenter Carey Lumeng MD PhD) [46]. For example, tissue-resident alveolar macrophages display a unique metabolic profile, influenced by the concentrations of glucose and lipids in the microenvironment [47].

Outstanding questions and challenges in the field include the mechanisms by which obesity modifies pulmonary and systemic immune responses, the role of microbiome alterations in

obesity on immune responses, the potential to harness nutrient flux and cellular metabolism to control immune responses, and the limitations of animal models to understand links between metabolism and myeloid cell activation.

Computational approaches to dissect microbiome-metabolite links

Studies of the human microbiome often reveal microbiome differences that vary with disease, or that correlate with disease phenotypes, but determining cause versus effect and the specific mechanisms at play are challenging. Dissecting mechanisms that involve metabolite mediators is a critical challenge. Small molecules present in host specimens typically represent a complex mixture of metabolites produced by the host, microbiota, or both; they also may be reflective of environmental exposures such as diet or from inhaled air [48]. There is a need for improved determination of the relative contribution of microbial and host metabolism to the metabolic environment (presenter Catherine Lozupone PhD). This would aid understanding of mediators of host-microbe interactions and their downstream effects. One avenue is to use information in databases on chemical reactions present in microbes and humans to predict which annotated metabolites, in an untargeted metabolome dataset, could have been produced by the host, the microbiome, both, or neither. To support this goal, a recently developed tool called AMON (Analysis of Metabolite Origins using Networks) [49] uses predicted gene sets from the microbiome and the KEGG database to annotate metabolites as to their potential origin. Although this approach and others similar such as MIMOSA [50] are helpful, they only can work on metabolites that are a part of well annotated pathways. The metabolomes of germ-free versus humanized gnotobiotic mice have been compared to assist in identifying small molecules influenced by the presence of microbiota [51]. This approach has the advantage of identifying poorly annotated small molecules but still cannot differentiate between direct

production/consumption by the microbiome versus indirect effects. Another weakness is that not all human microbes of interest may colonize mice used to study this or produce the same metabolites in that context.

Potential confounders of microbiome-disease associations in human studies

Another challenge of studies aiming to dissect microbiome links to disease is the inherent heterogeneity of the human microbiome, and the many endogenous and exogenous factors that modify it. The gut microbiota has been demonstrated to exert strong effects on numerous organ systems in many preclinical disease models [52]. Whether such links translate to humans, and which human gut bacteria mediate these effects, can be difficult to disentangle and thus often poorly understood. The primary method by which human microbiome science has sought to examine these questions has been the cross-sectional association study. Many such studies have found differences in the gut microbiota between cases and controls for prevalent diseases, including asthma. However, low concordance in microbiota results between such studies [53] (e.g., findings based on compositional differences) is a pervasive challenge that limits the capacity to infer causal relationships. The risk of obtaining false positives is exacerbated by interindividual heterogeneity in microbiota composition, probably due to population-wide differences in lifestyle and physiological variables that shape the microbiota. Incomplete knowledge of such variables can stymie accounting for such factors in human cross-sectional or longitudinal studies and contribute to overlooking of confounders.

Recent work [54] utilizing the largest known public database of human gut microbiota profiles aimed to determine the greatest, generalized sources of heterogeneity and their potential impact on disease associations (presenter Ivan Vujkovic-Cvijin PhD). Human lifestyle and physiological

characteristics were identified that, if not well-matched between cases and controls, confound microbiota analyses to produce spurious microbial associations with human diseases. Alcohol consumption frequency and bowel movement quality were unexpectedly strong sources of gut microbiota variance that differed in distribution between healthy participants and those with a disease []. For self-reported lung disease diagnoses, BMI was identified as a potential factor that differed between those with or without lung disease, though this was a broad category ('lung disease') and thus other microbiota-associated confounding factors may affect the study of specific lung diseases. In the study by Vujkovic-Cvijin et al. [54], for several prevalent diseases, matching cases and controls for potential confounding variables (e.g., age, sex, BMI, dietary intake, stool quality, others) reduced observed differences in the gut microbiota and the incidence of spurious associations with disease. Thus, attention to improved matching of subjects could increase the robustness and reproducibility in resolving members of the gut microbiota truly associated with disease. Additional tools such as identification of immunoglobulin-targeted gut bacteria could be leveraged to better understand which specific members of a microbiota elicit pathologic or homeostatic immune responses [55]. Future investigations to identify airway-resident microbes that may elicit such immune responses could consider interrogation of anti-microbiota IgA and/or IgE repertoires within lung mucosal fluids.

CONCLUSIONS

Ongoing challenges in asthma prevention and management highlight an urgent need for further mechanistic and translational studies to clarify drivers of variation in immune response patterns and clinical trajectories. There was broad consensus that multiple scientific challenges need to be bridged to better understand links between perturbed microbiome and metabolic states, and their collective impact on airway immune cell function and asthma pathophysiology. Key research

questions and gaps identified during the workshop are highlighted in **Box 1**. Recommendations for future research focus are presented in **Box 2**.

Several overarching conceptual questions were posed. Associative microbiome or metabolomic findings from human studies raise the perennial question of cause versus effect. It is inevitable, however, that multi-directional interactions are at play in biological systems. Thus, channeling efforts towards better understanding mechanisms of interaction between specific components in a system or niche could be more informative. For example, it is important to understand how microbiota (or a specific set of microbial functions) shape the airway metabolic milieu to promote lung immune responses to infectious agents or allergen immune tolerance. Also critical is understanding how intra- and extra-cellular metabolic conditions affect the function of specific immune cells. Such mechanistic insights could then support the development of interventions that are microbially and metabolically informed.

Hurdles remain in the technical and translational realm for applied human studies. Untargeted metabolomics approaches are hampered by incomplete databases that render identification of metabolites a major challenge. More knowledge is needed regarding which metabolites can be produced by specific microbes or are co-metabolized with the host, including real-time functional studies using *in vitro* and *in vivo* model systems. Multi-dimensional data analysis can be computationally challenging, coupled with a need for further statistical method development to accommodate data characteristics. Moreover, variables representing important host characteristics need to be integrated into such analyses to mitigate misinterpretation or confounding. Compared to the gut microbiome, the role of confounding factors in associative studies of the lower airway microbiome is less understood or appreciated, with exception of antibiotic exposures. Moreover, whether functions of lower airway microbiota, not just their

composition, vary in relation to factors unrelated to asthma is unknown. Finally, cross-study comparisons can be challenging due to differences in study design, technical platforms, and data analysis strategies. This can be addressed by careful and upfront study designs to yield maximally interpretable data and mechanism-oriented insights. Considerations include longitudinal and/or interventional studies, and importantly, more precise definition of asthma phenotypes, where applicable, to compare and interpret molecular, microbial, and immunologic findings. It could also be useful to include alternative or intermediate outcome measures that capture these biological readouts, to examine potential mechanistic links.

In conclusion, findings from this workshop highlighted recognized challenges but also exciting avenues for further development, that will lay the foundations to better understand the impact of perturbed microbiome and metabolic responses in asthma pathogenesis and outcomes. More attention to these aspects as potential proximal drivers of immunologic and clinical heterogeneity in asthma may lead to new and more precise strategies to alleviate asthma burden.

This workshop report was developed by an ad hoc subcommittee of the ATS and NIAID.

Yvonne J. Huang MD (Chair/speaker; lead organizer, writing/editing of report)

Fernando Holguin MD (Co-Chair/speaker, writing/editing of report)

Leopoldo N. Segal MD (Co-Chair; review/editing of report)

Talal A. Chatila MD (speaker; writing/editing of report)

Anne E. Dixon BM BCh (participant; review/editing of report)

James E. Gern MD (speaker; writing/editing of report)

Ariangela J. Kozik PhD (participant; writing/editing of report)

Catherine Lozupone PhD (speaker; writing/editing of report)

Nicholas Lukacs PhD (speaker; writing/editing of report)

Carey Lumeng MD PhD (speaker; writing/editing of report)

Philip L Molyneaux MD PhD (participant; review/editing of report)

Nichole Reisdorph PhD (participant; review/editing of report)

Ivan Vujkovic-Cvijin PhD (speaker; writing/editing of report)

Alkis Togias MD (participant; review/editing of report)

References.

1. Johnson CC, Chandran A, Havstad S, Li X, McEvoy CT, Ownby DR, et al. US Childhood Asthma Incidence Rate Patterns From the ECHO Consortium to Identify High-risk Groups for Primary Prevention. *JAMA Pediatr.* 2021 Sep 1;175(9):919–27.
2. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. *Lancet.* 2018 Feb 24;391(10122):783–800.
3. Hudey SN, Ledford DK, Cardet JC. Mechanisms of non-type 2 asthma. *Curr Opin Immunol.* 2020 Oct;66:123–8.
4. Lambrecht BN, Hammad H, Fahy JV. The Cytokines of Asthma. *Immunity.* 2019 Apr 16;50(4):975–91.
5. Budden KF, Shukla SD, Rehman SF, Bowerman KL, Keely S, Hugenholtz P, Armstrong-James DPH, Adcock IM, Chotirmall SH, Chung KF, Hansbro PM. Functional effects of the microbiota in chronic respiratory disease. *Lancet Respir Med.* 2019 Oct;7(10):907-920.
6. Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosch D, et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. *Nat Med.* 2016;22(10):1187–91.
7. Chiu C-Y, Chou H-C, Chang L-C, Fan W-L, Dinh MCV, Kuo Y-L, et al. Integration of metagenomics-metabolomics reveals specific signatures and functions of airway microbiota in mite-sensitized childhood asthma. *Allergy.* 2020 Nov;75(11):2846–57.
8. Teo SM, Tang HHF, Mok D, Judd LM, Watts SC, Pham K, et al. Airway Microbiota Dynamics Uncover a Critical Window for Interplay of Pathogenic Bacteria and Allergy in Childhood Respiratory Disease. *Cell Host Microbe.* 2018 12;24(3):341-352.e5.

9. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nat Med*. 2014 Feb;20(2):159–66.
10. Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. *J Allergy Clin Immunol*. 2017 Jul;140(1):63–75.
11. Kelly RS, Dahlin A, McGeachie MJ, Qiu W, Sordillo J, Wan ES, et al. Asthma Metabolomics and the Potential for Integrative Omics in Research and the Clinic. *Chest*. 2017 Feb;151(2):262–77.
12. Dixon AE, Holguin F. Diet and Metabolism in the Evolution of Asthma and Obesity. *Clin Chest Med*. 2019;40(1):97–106.
13. Williams EJ, Negewo NA, Baines KJ. Role of the NLRP3 inflammasome in asthma: Relationship with neutrophilic inflammation, obesity, and therapeutic options. *J Allergy Clin Immunol*. 2021 Jun;147(6):2060–2.
14. Wood LG, Li Q, Scott HA, Rutting S, Berthon BS, Gibson PG, et al. Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients. *J Allergy Clin Immunol*. 2019;143(1):305–15.
15. Pinkerton JW, Kim RY, Brown AC, Rae BE, Donovan C, Mayall JR, et al. Relationship between type 2 cytokine and inflammasome responses in obesity-associated asthma. *J Allergy Clin Immunol*. 2022 Apr;149(4):1270–80.
16. Makowski L, Chaib M, Rathmell JC. Immunometabolism: From basic mechanisms to translation. *Immunol Rev*. 2020 May;295(1):5–14.

17. Michaeloudes C, Bhavsar PK, Mumby S, Xu B, Hui CKM, Chung KF, et al. Role of Metabolic Reprogramming in Pulmonary Innate Immunity and Its Impact on Lung Diseases. *J Innate Immun*. 2020;12(1):31–46.
18. Runtsch MC, Angiari S, Hoofman A, Wadhwa R, Zhang Y, Zheng Y, et al. Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages. *Cell Metab*. 2022 Mar 1;34(3):487-501.e8.
19. Rago D, Pedersen C-ET, Huang M, Kelly RS, Gürdeniz G, Brustad N, et al. Characteristics and Mechanisms of a Sphingolipid-associated Childhood Asthma Endotype. *Am J Respir Crit Care Med*. 2021 Apr 1;203(7):853–63.
20. Harb H, Stephen-Victor E, Crestani E, Benamar M, Massoud A, Cui Y, et al. A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma. *Nat Immunol*. 2020 Nov;21(11):1359–70.
21. Harb H, Benamar M, Lai PS, Contini P, Griffith JW, Crestani E, et al. Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. *Immunity*. 2021 Jun 8;54(6):1186-1199.e7.
22. Sencio V, Machado MG, Trottein F. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes. *Mucosal Immunol*. 2021 Mar;14(2):296–304.
23. Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The Role of Lung and Gut Microbiota in the Pathology of Asthma. *Immunity*. 2020 Feb 18;52(2):241–55.
24. Fonseca W, Lucey K, Jang S, Fujimura KE, Rasky A, Ting H-A, et al. *Lactobacillus johnsonii* supplementation attenuates respiratory viral infection via metabolic reprogramming and immune cell modulation. *Mucosal Immunol*. 2017 Nov;10(6):1569–80.

25. Fonseca W, Malinczak C-A, Fujimura K, Li D, McCauley K, Li J, et al. Maternal gut microbiome regulates immunity to RSV infection in offspring. *J Exp Med*. 2021 Nov 1;218(11):e20210235.
26. Bisgaard H, Hermansen MN, Bønnelykke K, Stokholm J, Baty F, Skytt NL, et al. Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study. *BMJ*. 2010 Oct 4;341:c4978.
27. Bashir H, Grindle K, Vrtis R, Vang F, Kang T, Salazar L, et al. Association of rhinovirus species with common cold and asthma symptoms and bacterial pathogens. *J Allergy Clin Immunol*. 2018 Feb;141(2):822-824.e9.
28. Kloefer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, et al. Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. *J Allergy Clin Immunol*. 2014 May;133(5):1301–7, 1307.e1-3.
29. Kloefer KM, Sarsani VK, Poroyko V, Lee WM, Pappas TE, Kang T, et al. Community-acquired rhinovirus infection is associated with changes in the airway microbiome. *J Allergy Clin Immunol*. 2017 Jul;140(1):312-315.e8.
30. McCauley K, Durack J, Valladares R, Fadrosch DW, Lin DL, Calatroni A, et al. Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma. *J Allergy Clin Immunol*. 2019 Nov;144(5):1187–97.
31. Zhou Y, Jackson D, Bacharier LB, Mauger D, Boushey H, Castro M, et al. The upper-airway microbiota and loss of asthma control among asthmatic children. *Nat Commun*. 2019 16;10(1):5714.

32. Alnahas S, Hagner S, Raifer H, Kilic A, Gasteiger G, Mutters R, et al. IL-17 and TNF- α Are Key Mediators of *Moraxella catarrhalis* Triggered Exacerbation of Allergic Airway Inflammation. *Front Immunol*. 2017;8:1562.
33. Heinrich A, Heyl KA, Klaile E, Müller MM, Klassert TE, Wiessner A, et al. *Moraxella catarrhalis* induces CEACAM3-Syk-CARD9-dependent activation of human granulocytes. *Cell Microbiol*. 2016 Nov;18(11):1570–82.
34. Dohrman A, Miyata S, Gallup M, Li JD, Chapelin C, Coste A, et al. Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria. *Biochim Biophys Acta*. 1998 Apr 28;1406(3):251–9.
35. Zahlten J, Kim Y-J, Doehn J-M, Pribyl T, Hocke AC, García P, et al. *Streptococcus pneumoniae*-Induced Oxidative Stress in Lung Epithelial Cells Depends on Pneumococcal Autolysis and Is Reversible by Resveratrol. *J Infect Dis*. 2015 Jun 1;211(11):1822–30.
36. Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. *J Allergy Clin Immunol*. 2020 Oct;146(4):685–93.
37. Bhatraju NK, Agrawal A. Mitochondrial Dysfunction Linking Obesity and Asthma. *Ann Am Thorac Soc*. 2017 Nov;14(Supplement_5):S368–73.
38. Yamamoto M, Tochino Y, Chibana K, Trudeau JB, Holguin F, Wenzel SE. Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation. *Clin Exp Allergy*. 2012 May;42(5):760–8.
39. Grasemann H, Holguin F. Oxidative stress and obesity-related asthma. *Paediatr Respir Rev*. 2021 Mar;37:18–21.

40. Xu W, Ghosh S, Comhair SAA, Asosingh K, Janocha AJ, Mavrakakis DA, et al. Increased mitochondrial arginine metabolism supports bioenergetics in asthma. *J Clin Invest*. 2016 Jul 1;126(7):2465–81.
41. Peters U, Dixon AE, Forno E. Obesity and asthma. *J Allergy Clin Immunol*. 2018 Apr;141(4):1169–79.
42. Winnica D, Corey C, Mullett S, Reynolds M, Hill G, Wendell S, et al. Bioenergetic Differences in the Airway Epithelium of Lean Versus Obese Asthmatics Are Driven by Nitric Oxide and Reflected in Circulating Platelets. *Antioxid Redox Signal*. 2019 Oct 1;31(10):673–86.
43. Mancuso P. Obesity and lung inflammation. *J Appl Physiol* (1985). 2010 Mar;108(3):722–8.
44. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas M-E. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. *Genome Med*. 2016 Apr 20;8(1):42.
45. Singh RK, Chang H-W, Yan D, Lee KM, Ucmak D, Wong K, et al. Influence of diet on the gut microbiome and implications for human health. *J Transl Med*. 2017 Apr 8;15(1):73.
46. Russo L, Lumeng CN. Properties and functions of adipose tissue macrophages in obesity. *Immunology*. 2018 Dec;155(4):407–17.
47. Woods PS, Kimmig LM, Meliton AY, Sun KA, Tian Y, O’Leary EM, et al. Tissue-Resident Alveolar Macrophages Do Not Rely on Glycolysis for LPS-induced Inflammation. *Am J Respir Cell Mol Biol*. 2020 Feb;62(2):243–55.
48. Shaffer M, Armstrong AJS, Phelan VV, Reisdorph N, Lozupone CA. Microbiome and metabolome data integration provides insight into health and disease. *Transl Res*. 2017 Nov;189:51–64.

49. Shaffer M, Thurimella K, Quinn K, Doenges K, Zhang X, Bokatzian S, et al. AMON: annotation of metabolite origins via networks to integrate microbiome and metabolome data. *BMC Bioinformatics*. 2019 Nov 28;20(1):614.
50. Noecker C, Eng A, Srinivasan S, Theriot CM, Young VB, Jansson JK, et al. Metabolic Model-Based Integration of Microbiome Taxonomic and Metabolomic Profiles Elucidates Mechanistic Links between Ecological and Metabolic Variation. *mSystems*. 2016 Feb;1(1):e00013-15.
51. Marcobal A, Kashyap PC, Nelson TA, Aronov PA, Donia MS, Spormann A, et al. A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. *ISME J*. 2013 Oct;7(10):1933–43.
52. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol*. 2021 Jan;19(1):55–71.
53. Abdel-Aziz MI, Vijverberg SJH, Neerincx AH, Kraneveld AD, Maitland-van der Zee AH. The crosstalk between microbiome and asthma: Exploring associations and challenges. *Clin Exp Allergy*. 2019 Aug;49(8):1067–86.
54. Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y. Host variables confound gut microbiota studies of human disease. *Nature*. 2020 Nov;587(7834):448–54.
55. Weis AM, Round JL. Microbiota-antibody interactions that regulate gut homeostasis. *Cell Host Microbe*. 2021 Mar 10;29(3):334–346.




Figure 1. Shifts in microbiome functions and metabolic states have the capacity to shape immune responses and asthma outcomes across the lifespan. Created with BioRender.com.

Box 1. Major gaps and challenges for understanding the intersecting effects of microbiota, metabolism, and immune responses on asthma pathogenesis and phenotypes.

Conceptual	• Does the microbiome promote changes in immunity through particular metabolite production profiles? • What are the mechanisms that program lung immune responses to infectious agents and immune tolerance to allergens, and what is the contribution of microbiota (bacteria, fungi, and viruses) of the airways vs the gut? • What are the contributions of direct (e.g. diet) and indirect disrupted metabolism to altered function of myeloid cells impacting asthma? • How do commensal bacteria help to maintain normal airway physiology? • Does an altered microbiome promote asthma in an already predisposed host, or does it actually induce the disease? • Can appropriate immune responses to infectious agents or immune tolerance to allergens be re-established in the chronically inflamed airways? If so, how?
Technical	• Untargeted metabolomics approaches limited by incomplete databases and unreliable identification of metabolites • Links between microbiota and metabolites - gaps in knowledge regarding what microbiota directly produce, metabolize, or co-metabolize with hosts • Need for standardized and robust methods for integrating and analyzing multi-dimensional data; sample size requirements • Capturing and evaluating potential confounding variables that can influence microbial or metabolic associations with disease
Translational	• What aspects of the maternal microbiome contribute to infant immune functions and how does this compare to the role of developmental changes of the infant microbiome during early childhood? In utero or post-natal? • What aspects of the airway microbiome shape airway immune response patterns during early life and how do these differ between asthma phenotypes? • What is the relative contribution of changes in local (airway milieu) vs. systemic metabolism on airway immune cell functions and pathophysiology in asthma? • Can the airway microbiome be modified to promote commensal bacteria or revert dysbiosis associated with asthma?

Box 2. Suggestions for Future Research.

Basic, Translational	• Studies of host immune response in relation to metabolic and microbiome profiles • Studies of the nutrient environment in the context of allergic inflammation • Studies of the intersecting mechanisms involving gut microbiota, formation of specific metabolic products, and effects on airway immune responses in asthma • Studies to understand how airway commensals and pathogens interact with mucosal immunity to modify airway function in asthma • Studies of microbiome alterations, metabolism and immune pathway interactions in obesity and asthma
Technical	• Expanded sample collections from different biological compartments to enable systems-based analyses • Benchmarking studies to define concordance between measured relative levels of metabolites and actual production • Generation and integration of multi-omic data to dissect the mechanisms of microbial or metabolic effects on immune responses • Further development of statistical approaches for multi-dimensional data analysis
Clinical	• Improved study designs that can support more robust analyses or exploration of mechanisms. Considerations, ideas include: ○ Longitudinal studies to increase analytical robustness and capture time effects ○ Larger sample sizes to capture sub-phenotypes/endotypes and interactions ○ Studies of the developmental trajectory of the airway microbiome in healthy vs. asthmatic children ○ Studies to examine microbial, metabolic and immunologic interactions in asthma during adolescent to adult transition with focus on sex differences and on obesity ○ More precise definition of phenotypes and sub-phenotypes to better interpret comparative findings (e.g. obesity-induced vs. obesity-complicated asthma; adult-onset vs. late-onset) ○ Timing of sample collections to enable comparisons at baseline and follow up post-therapeutic intervention. ○ Thorough determination of endogenous and exogenous variables that may influence or confound microbial or metabolism-related associations with asthma ○ Promotion of inclusion of mechanistic outcomes in phase 2 clinical trials ○ Development of strategies for collection and appropriate storage of samples that can be used for immune marker, microbiome and metabolome profiling in clinical trials and observational studies